VPS Healthcare’s medicine manufacturing arm, LIFEPharma, will explore entering into the European and American markets, as part of a major step towards transforming the region as a hub for pharmaceutical production and export.

Initially, the company will be exporting around 25,000 bottles of Acetazolamide collaborating with Eywa, a leading pharmaceutical production company in the US, company officials said at the Arab Health Summit, held last month in Dubai, UAE.

The first batch of the medicines, locally produced at LIFEPharma’s production plant in Jebel Ali, were scheduled to be exported last month. Subsequently, the unit will be manufacturing and exporting more products, particularly in the cardiovascular and diuretic therapy areas.

Apart from this, on the backdrop of Arab Health, LIFEPharma struck a major deal with leading European multinational company, XO Laboratory, based in France.

As per the MoU signed between the entities, LIFEPharma will be producing a significant number of XO’s products locally in the UAE and import unique medicines such as Alendronic acid solution, Mynocycline, Alginic acide sachets and Ketoprofen/Omeprazole from France to the UAE market. The MoU was signed by LIFEPharma CEO Dr Madgy Fahmy and XO Laboratory director general Karine Pinon in the presence of VPS Healthcare chairman and managing director Dr Shamsheer Vayalil.

In 2019, LifePharma had signed a significant deal with Canadian giant Apotex, the largest producer of generic medicines in North America, to produce generic medicines to be exported to North American markets.